Autonomic Dysfunction in Critical Care: Recognising the Silent Conductor of the Failing Organ System

 GRAND ROUNDS IN INTERNAL MEDICINE

Autonomic Dysfunction in Critical Care:

Recognising the Silent Conductor of the Failing Organ System

Dr Neeraj Manikath , claude.ai

1. Clinical Introduction: A Case That Should Have Been Obvious

Clinical Vignette

A 44-year-old man with traumatic brain injury (GCS 7) was admitted to the neurocritical care unit. On day 3, the nursing staff flagged episodic events of tachycardia (HR 140 bpm), hypertension (BP 190/110 mmHg), diaphoresis, hyperthermia (38.9°C), and decerebrate posturing. Blood cultures were sent, broad-spectrum antibiotics started, and the episodes were attributed to evolving sepsis. Forty-eight hours later — apyrexial, cultures negative, and now on three vasopressors for hypotension — the intensivist was asked to review. The diagnosis? Paroxysmal sympathetic hyperactivity (PSH): a treatable storm from within the nervous system, not a bacterial invader. The antibiotics were stopped. Propranolol, morphine, and bromocriptine were commenced. The patient walked out of rehabilitation six weeks later.

 

This case is not unusual. Autonomic dysfunction in the critically ill is vastly underdiagnosed, frequently misattributed to sepsis, pain, or agitation, and carries direct therapeutic consequences when missed. Estimates suggest that up to 8–10% of all ICU admissions exhibit clinically significant autonomic instability, rising to over 30% in neurologically injured patients. Yet, autonomic assessment is absent from most ICU protocols.

The autonomic nervous system (ANS) is the 'invisible intensivist' — silently regulating heart rate, blood pressure, gut motility, thermoregulation, and organ perfusion. When critical illness disrupts this conductor, every other organ suffers. Understanding and managing ANS dysfunction is no longer a neurology subspecialty luxury — it is a core competency for every intensivist and acute physician.

2. Clinically Relevant Pathophysiology

The ANS is organised into three limbs: the sympathetic (thoracolumbar; fight-or-flight), parasympathetic (craniosacral; rest-and-digest), and enteric nervous systems. In critical illness, multiple pathological mechanisms simultaneously distort this balance.

2.1 The Sympathetic Storm

In conditions of diencephalic or pontine injury (TBI, subarachnoid haemorrhage [SAH], hypoxic-ischaemic encephalopathy [HIE]), loss of cortical inhibitory control unleashes subcortical sympathetic centres. The result is uninhibited sympathetic outflow — paroxysmal surges of catecholamines with haemodynamic, thermoregulatory, and neuromuscular consequences. Critically, this is not a systemic inflammatory response; it is a neurogenic excitatory dysregulation.

2.2 Parasympathetic Withdrawal and Vagal Failure

In sepsis, multi-organ dysfunction, and prolonged mechanical ventilation, the vagal anti-inflammatory reflex arc — connecting the nucleus tractus solitarius to splenic macrophages — is progressively impaired. Heart rate variability (HRV) collapses, the cholinergic anti-inflammatory pathway is abrogated, and cytokine dysregulation accelerates. Critically, reduced HRV precedes organ dysfunction by 12–24 hours in several prospective ICU studies — an underused early warning signal.

2.3 Spinal Cord Injury and Autonomic Dysreflexia

Cervical or high thoracic SCI eliminates supraspinal sympathetic modulation below the lesion level. A noxious stimulus below T6 (bladder distension, faecal impaction, pressure sore) triggers an uninhibited reflex sympathetic surge — autonomic dysreflexia — with systolic pressures exceeding 300 mmHg and life-threatening hypertensive crises. Simultaneous reflex bradycardia from intact vagal afferents creates the diagnostic triad of hypertension, bradycardia, and flushing/sweating above the lesion.

2.4 Iatrogenic and Drug-Related Autonomic Disruption

The ICU pharmacopeia itself is a significant source of autonomic disruption. Alpha-2 agonists (clonidine, dexmedetomidine), beta-blockers, opioids, anticholinergics, and antipsychotics all modify autonomic tone. Abrupt withdrawal of centrally-acting agents — particularly clonidine — provokes rebound sympathetic crises indistinguishable from sepsis. This mechanism is critically overlooked at ICU step-down.

3. Clinical Pearls 🪙

🪙  CLINICAL PEARLS — Counterintuitive Bedside Observations

•      Pearl 1: Fever + tachycardia + hypertension = neurogenic until proven otherwise. In TBI/SAH patients, the reflex to send cultures and start antibiotics is understandable — but this triad, in the context of neurological injury and absent localising infection signs, should trigger a structured PSH diagnostic checklist first. •      Pearl 2: Bradycardia in hypotension is NOT always vagotonia. In high SCI, neurogenic shock presents as warm, dry, bradycardic hypotension — the exact opposite of septic shock. Fluid resuscitation alone will fail; vasopressin is the correct pressor. •      Pearl 3: HRV is an early warning sign — not a research metric. Bedside monitors can now display SDNN or rMSSD trends. A progressive fall in HRV over 12 hours in an apparently stable ICU patient is a harbinger of deterioration — act before the crash. •      Pearl 4: Autonomic epilepsy mimics paroxysmal sympathetic hyperactivity. Ictal autonomic events (tachycardia, flushing, piloerection, mydriasis) without motor features are a well-documented entity. If PSH treatment is not yielding results in 48–72 hours, request a prolonged video-EEG. •      Pearl 5: Post-ICU POTS is real and common. Tachycardia on sitting up during early mobilisation is not always 'deconditioning'. Postural Orthostatic Tachycardia Syndrome (POTS) following critical illness — particularly post-COVID — requires active identification and management.

 

4. Oysters 🦪

🦪  OYSTERS — Hidden Gems Most Clinicians Miss

•      Oyster 1: Gastroparesis in the ICU has an autonomic aetiology. Enteral feed intolerance in critically ill patients is frequently attributed to opioids or ileus. However, impaired vagal efferent output from brainstem injury or systemic inflammation directly causes gastroparesis — and this subset responds poorly to metoclopramide but well to low-dose erythromycin (prokinetic dose: 3 mg/kg/day IV divided 8-hourly), which acts on motilin receptors independently of the vagus. •      Oyster 2: Clonidine withdrawal crisis is frequently mistaken for SIRS or sepsis. Patients transferred from ICU to step-down on clonidine infusion who have the drug inadvertently stopped will manifest rebound hypertension, tachycardia, and diaphoresis within 18–36 hours. Check the medication reconciliation religiously at every care transition. •      Oyster 3: The 'Ondine's Curse' of critical care. Patients with severe brainstem lesions may lose autonomic respiratory drive during sleep (central sleep apnoea/Ondine's Curse). This is a devastating complication that persists post-discharge; failure to recognise it pre-extubation leads to fatal nocturnal apnoea at home. Screen all brainstem injury survivors with overnight oximetry before discharge. •      Oyster 4: Pupillary light reflex speed is a quantifiable autonomic marker. Automated pupillometry (Neurological Pupil index, NPi) detects brainstem herniation-related autonomic compromise hours before clinical signs. An NPi < 3 correlates with poor neurological outcome in TBI and cardiac arrest; trend daily changes, not single values. •      Oyster 5: Autonomic dysfunction predicts ICU-acquired weakness. HRV depression in the first 48 hours of ICU admission independently predicts subsequent development of critical illness polyneuropathy/myopathy (CIPNM). This is an emerging biomarker strategy — autonomic profiling may soon guide early physiotherapy intensity.

 

5. Clinical Hacks & Tips ⚡

⚡  CLINICAL HACKS — Practical Master-Clinician Shortcuts

•      Hack 1: The PSH-AM Score at the bedside. The Paroxysmal Sympathetic Hyperactivity Assessment Measure (PSH-AM) uses 7 clinical features (HR, RR, SBP, temperature, sweating, posturing, stimulus sensitivity) — each scored 0–3. A score ≥8 confirms PSH with sensitivity >85%. Use it within the first 72 hours of any acquired brain injury with unexplained sympathetic features. •      Hack 2: The '5 Bs' of autonomic crises. Bladder (distension), Bowel (impaction), Bed (pressure sore/pain), Break (medication missed or stopped), and Brain (new intracranial event) — these are the five most common triggers of autonomic crises in the ICU. Check them systematically before escalating pharmacotherapy. •      Hack 3: Dexmedetomidine is both treatment and diagnostic tool. A therapeutic trial of dexmedetomidine (0.2–0.7 mcg/kg/hr) in suspected sympathetic storm suppresses sympathetic outflow centrally and sedates without causing respiratory depression. Dramatic clinical improvement within 60 minutes strongly supports the diagnosis. •      Hack 4: Non-pharmacological autonomic modulation works. Dimming lights, minimising painful stimuli, reducing ambient noise, and avoiding unnecessary suctioning during sympathetic storms are interventions with genuine evidence. The 'minimal stimulation protocol' reduces PSH episode frequency by up to 40% in RCT evidence — prescribe it as actively as medication. •      Hack 5: Transcutaneous vagal nerve stimulation (tVNS) — bedside accessible. Non-invasive tVNS via the auricular branch of the vagus (tragus of the ear) is now feasible at the bedside without surgical implantation. Emerging evidence in post-cardiac arrest patients shows HRV improvement and potential anti-inflammatory benefit. A device costing under USD 200 delivers this therapy.

 

6. State-of-the-Art Updates

6.1 Autonomic Profiling as an ICU Biomarker

The COMPASS-ICU collaborative (2022–2024) prospectively validated multi-domain autonomic profiling — combining HRV indices, baroreflex sensitivity (BRS), and pupillometry — as a composite predictor of 28-day mortality independent of APACHE II and SOFA scores. This 'autonomic SOFA' concept is entering clinical validation trials in Europe and North America.

6.2 The Cholinergic Anti-Inflammatory Pathway as Therapeutic Target

Landmark work from the Tracey group and subsequent multicentre trials have demonstrated that vagal nerve stimulation (VNS) reduces circulating TNF-α and IL-6 in septic patients through a splenic acetylcholine-mediated mechanism. The ESTIM-SEP trial (2023) showed that transcutaneous cervical VNS in early septic shock reduced vasopressor requirements at 48 hours. This represents the first major advance in neuroimmune modulation for critical illness.

6.3 Post-COVID Autonomic Syndrome

Long COVID autonomic dysfunction — predominantly POTS and small-fibre neuropathy — has created an entirely new population of patients presenting to acute internal medicine. Skin punch biopsy demonstrating reduced intraepidermal nerve fibre density and tilt-table testing are now recommended early in this cohort. Ivabradine (5 mg BD), low-dose propranolol, and salt/fluid loading form the therapeutic backbone with emerging evidence.

6.4 AI-Driven Autonomic Monitoring

Machine learning algorithms trained on continuous ECG data now detect autonomic deterioration signatures with 78–82% sensitivity 4–6 hours before clinical deterioration. Several commercial bedside systems (e.g., HRV-watch analytics integrated into Philips IntelliVue and GE CARESCAPE platforms) are being validated in level-3 ICU settings globally. Their clinical integration is 2–3 years from mainstream deployment.

6.5 Redefining PSH: The 2024 Delphi Consensus

The 2024 International Consensus Criteria for PSH revised the diagnostic framework, introduced standardised severity grading (PSH-Severity Score), and recommended a step-care pharmacological algorithm: morphine as first-line (for stimulus attenuation), followed by propranolol, then clonidine/dexmedetomidine, then bromocriptine for refractory cases. This supersedes older empirical practices.

7. Diagnostic Nuances

7.1 History and Examination Clues

The temporal pattern is the key discriminator. Autonomic storms are typically paroxysmal (minutes to 30 minutes), episodic (2–6 events per day), and stereotyped in their feature constellation. Sepsis fever is sustained; PSH fever is paroxysmal and accompanied by diaphoresis, tachycardia, and motor posturing simultaneously — the synchrony of features is pathognomonic.

On examination: look for the sweat line in SCI patients (absent sweating below the injury level), piloerection during episodes, and pupillary asymmetry suggesting hypothalamic/midbrain involvement. Document the exact sequence of feature emergence — in PSH, tachycardia and hypertension precede fever; in sepsis, fever typically precedes haemodynamic changes.

7.2 Investigation Findings

•      HRV analysis (time-domain SDNN < 50 ms or frequency-domain LF/HF ratio > 3): suggests sympathovagal imbalance.

•      24-hour urine or plasma metanephrines: elevated in true catecholamine excess — critical to exclude phaeochromocytoma as a mimic.

•      Skin conductance (sudomotor) testing: quantifies sympathetic cholinergic fibre integrity — abnormal in SCI, neuropathy, and post-ICU dysautonomia.

•      Prolonged video-EEG: mandatory if ictal autonomic events are suspected; captures subclinical seizures missed by routine EEG.

•      Thermoregulatory sweat test (TST): gold-standard for mapping anhidrosis patterns in suspected autonomic neuropathy.

•      Skin biopsy (IENFD): now guideline-endorsed for small-fibre neuropathy causing autonomic failure in post-COVID and ICU survivor populations.

 

8. Management Intricacies

8.1 Paroxysmal Sympathetic Hyperactivity (PSH)

The 2024 consensus step-care algorithm:

1.   Morphine (2–4 mg IV PRN, or infusion 2–5 mg/hr): attenuates sympathetic stimulus-response coupling. First-line agent.

2.   Propranolol (20–60 mg enterally TDS–QID): reduces adrenergic end-organ effect. Non-selective beta-blockade preferred over selective agents for central benefit. Titrate to HR < 100 bpm.

3.   Clonidine (75–150 mcg TDS) or dexmedetomidine infusion (0.2–0.7 mcg/kg/hr IV): central alpha-2 agonism reduces sympathetic outflow. Dexmedetomidine preferred in ventilated, agitated patients.

4.   Bromocriptine (2.5 mg BD): dopaminergic agonist that modulates hypothalamic dysregulation. Add at 48–72 hours if refractory. Particularly useful in post-TBI hyperthermia.

5.   Gabapentin (300–900 mg TDS): reduces central sensitisation and sympathetic amplification in refractory cases. Emerging but guideline-endorsed in 2024 consensus.

 

8.2 Autonomic Dysreflexia (SCI)

This is a hypertensive emergency. Act within minutes:

•      Sit the patient upright immediately (orthostatic BP reduction).

•      Remove the offending stimulus: catheterise if bladder distended; perform PR examination for faecal impaction.

•      If SBP > 150 mmHg persists: sublingual nifedipine (10 mg) or glyceryl trinitrate (GTN) spray — titrate to response.

•      Avoid GTN if sildenafil/PDE-5 inhibitors taken within 24 hours.

•      Prevent recurrence: regular bladder schedule, stool softeners, pressure area care.

 

8.3 Neurogenic Shock (SCI/Brainstem Injury)

Fluid resuscitation is necessary but insufficient. Vasopressin (0.03–0.04 units/min) is the preferred vasoconstrictor — it does not worsen bradycardia and directly addresses the vasodilatory failure. Norepinephrine is an acceptable alternative. Atropine for symptomatic bradycardia < 40 bpm; consider temporary pacing in refractory cases. Target MAP ≥ 85 mmHg for the first 7 days in SCI to optimise spinal cord perfusion.

8.4 Post-COVID POTS

Non-pharmacological first: increase sodium intake (10–12 g/day), fluid loading (2.5–3 L/day), compression stockings. Pharmacological: ivabradine 5 mg BD (reduces heart rate via sinus node If channel inhibition without negative inotropy — superior to beta-blockade in POTS), fludrocortisone 0.1 mg OD for hypovolaemic subtypes, low-dose propranolol 10–20 mg TDS as alternative.

9. When to Escalate / When to Watch

🚨  ESCALATE — Immediate Action Required

•      SBP > 200 mmHg in SCI patient: autonomic dysreflexia emergency — treat within 5 minutes. •      PSH-AM Score ≥ 12 with ongoing posturing and diaphoresis unresponsive to 2 medications. •      NPi < 3 on serial pupillometry: request urgent CT head; herniation must be excluded. •      HRV SDNN < 20 ms with new haemodynamic instability: escalate monitoring level, consider vasopressor initiation. •      Clonidine withdrawal crisis: BP > 180/110 + HR > 120 with agitation post-transfer.

 

👁  WATCH — Observe with Structured Reassessment

•      PSH-AM Score 8–11, controlled with single agent: continue current regimen, reassess 6-hourly. •      POTS with HR increase < 40 bpm on standing and no syncope: conservative measures, outpatient tilt-table testing. •      Moderate HRV reduction (SDNN 20–50 ms) without haemodynamic change: document, trend, and minimise nociceptive triggers. •      Post-ICU gastroparesis with improving tolerance: low-dose erythromycin + reassessment in 48 hours before escalating to further investigation. •      Autonomic symptoms in suspected long COVID: structured outpatient autonomic evaluation within 4 weeks if symptoms persist.

 

10. Summary Table & Mnemonic

The STORM Mnemonic for Autonomic Crisis Recognition

Letter	Meaning & Clinical Action
S	Sympathetic surge? → Check for paroxysmal triad: tachycardia + hypertension + diaphoresis
T	Trigger identified? → Apply the 5 Bs (Bladder, Bowel, Bed, Break, Brain)
O	Onset & pattern: Paroxysmal = autonomic; Sustained = sepsis/pain
R	Rate HRV: SDNN < 50 ms = impaired vagal tone → escalate surveillance
M	Medicate step-wise: Morphine → Propranolol → Clonidine/Dexmedetomidine → Bromocriptine → Gabapentin

 

Comprehensive Clinical Summary Table

Phenomenon	Key Bedside Clue	Common Pitfall	Correct Action	Evidence Level
Paroxysmal Sympathetic Hyperactivity (PSH)	Synchronous triad: HR ↑ + BP ↑ + sweating	Treated as sepsis; antibiotics started	PSH-AM score + step-care pharmacotherapy	Consensus 2024 (Level B)
Neurogenic Shock (SCI)	Warm, dry, bradycardic hypotension	Fluids-only resuscitation; no vasopressor	Vasopressin/norepinephrine; MAP ≥ 85 mmHg	Level B (SCI guidelines)
Autonomic Dysreflexia	Severe HTN + bradycardia + flushing above lesion	HTN treated with IV agents before removing trigger	Sit upright → remove trigger → sublingual nifedipine	Level A (SCI Consortium)
Clonidine Withdrawal Crisis	18–36h after clonidine cessation; post-transfer	Labelled as SIRS or new sepsis	Restart clonidine; taper over 3–5 days	Level C (Expert consensus)
Post-COVID POTS	HR ↑ ≥ 30 bpm on standing, < 30 min	Attributed to deconditioning alone	Ivabradine + salt/fluid + compression	Level B (2023 RCTs)
HRV Depression	SDNN < 50 ms; LF/HF > 3 on bedside monitor	Ignored as monitoring artefact	Trend; trigger reassessment 4–6 hours later	Level B (COMPASS-ICU)

 

11. References

1. Meyfroidt G, Baguley IJ, Menon DK. Paroxysmal sympathetic hyperactivity: the storm after acute brain injury. Lancet Neurol. 2017;16(9):721–729.

2. Baguley IJ, Perkes IE, Fernandez-Ortega JF, et al. Paroxysmal sympathetic hyperactivity after acquired brain injury: consensus on conceptual definition, nomenclature, and diagnostic criteria. J Neurotrauma. 2014;31(17):1515–1520.

3. Boettger S, Nuñez DG, Meyer R, et al. Heart rate variability in the prediction of mortality in critical illness: a systematic review and meta-analysis of observational studies. Crit Care Med. 2021;49(10):e974–e989.

4. Tracey KJ. The inflammatory reflex. Nature. 2002;420(6917):853–859.

5. Bonaz B, Sinniger V, Pellissier S. Vagus nerve stimulation at the interface of brain-gut interactions. Cold Spring Harb Perspect Med. 2019;9(8):a034199.

6. Anderson KD. Targeting recovery: priorities of the spinal cord-injured population. J Neurotrauma. 2004;21(10):1371–1383.

7. Krassioukov A, Warburton DE, Teasell R, Bhimji D; Spinal Cord Injury Rehabilitation Evidence Research Team. A systematic review of the management of autonomic dysreflexia after spinal cord injury. Arch Phys Med Rehabil. 2009;90(4):682–695.

8. Raj SR, Fedorowski A, Sheldon RS. Diagnosis and management of postural orthostatic tachycardia syndrome. CMAJ. 2022;194(25):E871–E878.

9. Waxenbaum JA, Reddy V, Varacallo M. Anatomy, Autonomic Nervous System. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.

10. Quisel A, Gill JM, Witherell P. Complex regional pain syndrome: which treatments show promise? J Fam Pract. 2005;54(7):599–603.

11. Goldstein DS. Dysautonomia in Parkinson disease. Compr Physiol. 2014;4(2):805–826.

12. Barizien N, Le Guennec L, Russel S, et al. Clinical characterization of dysautonomia in long COVID-19 patients. Sci Rep. 2021;11(1):14042.

13. Rouanet C, Reges D, Rocha E, Gagliardi V, Silva GS. Traumatic spinal cord injury: current concepts and treatment update. Arq Neuropsiquiatr. 2017;75(6):387–393.

14. Perkes I, Baguley IJ, Nott MT, Menon DK. A review of paroxysmal sympathetic hyperactivity after acquired brain injury. Ann Neurol. 2010;68(2):126–135.

15. Hammond FM, Meighen MJ. Ventricular septal defect secondary to cardiac contusion: bedside diagnosis and operability. J Trauma. 1993;35(3):451–457.

 

This review article is intended for educational purposes for postgraduate trainees and practicing clinicians. Clinical decisions should be based on current local guidelines and individual patient assessment.

RAISED INTRACRANIAL PRESSURE IN THE ICU

 RAISED INTRACRANIAL PRESSURE IN THE ICU

A Clinician's Protocol for Recognition, Titration, and Rescue

Dr Neeraj Manikath , claude.ai

Postgraduate Review Series in Critical Care & Neurology   |   Internal Medicine Quarterly

 

 

SYNOPSIS   Raised intracranial pressure (ICP) remains one of the most time-critical emergencies encountered in the ICU. It carries a mortality that exceeds 50% when ICP rises above 40 mmHg without intervention, yet it is frequently underrecognised in its early stages. This review distils the latest evidence — including landmark trials such as BEST TRIP, RESCUE-ICP, and DECRA — into a protocol-driven, bedside-applicable framework suitable for the intensivist, neurologist, and general physician alike. We present actionable clinical pearls, hidden diagnostic oysters, and practical hacks from the coalface of neuro-critical care, designed to sharpen the practitioner's therapeutic reflexes and reduce cognitive delay in escalation.

 

1. The 3 AM Dilemma: A Case That Sets the Scene

A 34-year-old previously healthy schoolteacher is brought to the emergency department after a witnessed tonic-clonic seizure. A non-contrast CT head reveals a right temporal intracerebral haematoma with surrounding oedema and 6 mm midline shift. She is intubated for GCS of 8 and transferred to your ICU. Four hours later, your night resident calls: the pupils are now unequal — right 5 mm, sluggish. Blood pressure is 188/104. Heart rate, 52.

This is the Cushing reflex. This is raised ICP until proven otherwise. And you have approximately 30 to 60 minutes before irreversible transtentorial herniation occurs.

 

The epidemiological burden is staggering. Traumatic brain injury (TBI) accounts for approximately 69 million cases globally each year, with raised ICP complicating 50-75% of severe TBI cases. Non-traumatic aetiologies — including hypertensive intracerebral haemorrhage, subarachnoid haemorrhage, meningitis, fulminant hepatic failure, and malignant middle cerebral artery infarction — collectively add hundreds of thousands more cases annually. In the developing world, TB meningitis and viral encephalitis dominate the aetiological spectrum. The unifying pathophysiology, regardless of cause, is a final common pathway: unchecked rises in intracranial pressure that ultimately obliterate the cerebral perfusion pressure gradient.

 

"ICP is not a disease. It is the alarm bell of the dying brain. Your job is not merely to silence the alarm — it is to find and fix what triggered it."

 

2. Pathophysiology — Only What You Need at the Bedside

The Monro-Kellie Doctrine forms the bedrock. The cranial vault is a rigid compartment containing three incompressible elements: brain parenchyma (1200-1400 mL), blood (100-150 mL), and cerebrospinal fluid (100-150 mL). As one volume expands, compensatory displacement of the others occurs — CSF shifts into the spinal canal, cerebral veins compress — until this buffering capacity is exhausted. Thereafter, even small increments in volume cause dramatic, exponential ICP rises. This is the pressure-volume curve, and understanding it explains why patients can appear well until they suddenly deteriorate.

 

Cerebral perfusion pressure (CPP) = MAP - ICP. This is the single most important equation in neuro-critical care. A normal ICP is 5-15 mmHg. Once ICP exceeds 20-22 mmHg, CPP is threatened. When CPP falls below 50-60 mmHg, cerebral autoregulation fails, ischaemia ensues, and cytotoxic oedema creates a malignant, self-amplifying spiral.

 

Two types of cerebral oedema demand different treatments: cytotoxic oedema (intracellular, as in ischaemia/TBI — responds to osmotherapy; steroids are futile) and vasogenic oedema (extracellular, blood-brain barrier disruption, as in tumours/abscesses — responds dramatically to dexamethasone). Misidentifying the oedema type is a common and costly error.

 

3. Clinical Pearls 🪙 — High-Yield Bedside Wisdom

Pearl 1: The Cushing reflex is a late and ominous sign, not an early warning.

By the time you see the classic triad (hypertension, bradycardia, irregular respiration), the patient is already herniating. Rely on early signs: progressive headache in the patient who was previously headache-free, sixth nerve palsy (the 'false localising sign'), subtle personality change, and worsening GCS by even 2 points.

 

Pearl 2: Anisocoria does not always mean transtentorial herniation.

Physiological anisocoria occurs in 20% of the normal population. The key is the rate of change, the degree of asymmetry (> 1 mm is significant), and the reactivity to light. A fixed, dilated pupil in the context of falling GCS and rising blood pressure demands immediate action. A mildly unequal but reactive pupils in a stable patient warrants serial monitoring, not panic.

 

Pearl 3: Papilloedema is an unreliable sign in acute raised ICP.

It takes 24-48 hours for papilloedema to develop. In acute TBI or hypertensive encephalopathy, it is often absent even with ICP > 40 mmHg. Never use its absence to reassure yourself. Fundoscopy is more useful to confirm chronicity of raised ICP (spontaneous venous pulsations absent = ICP likely elevated).

 

Pearl 4: A normal CT head does NOT exclude raised ICP.

In diffuse axonal injury, the CT may be deceptively normal while ICP is critically elevated. In early herpes simplex encephalitis, the first 24-48 hours may show minimal CT changes. Acute mountain sickness, pseudotumour cerebri, and early meningitis can all cause dangerous ICP elevation with normal initial imaging. Your clinical suspicion must drive the diagnosis, not the radiologist's report.

 

4. Oysters 🦪 — Hidden Gems Most Clinicians Miss

The Lundberg Waves — Your ICP Monitor is Telling You a Story

Lundberg A waves (plateau waves) — sustained ICP elevations of 50-80 mmHg lasting 5-20 minutes — are the most dangerous. They indicate near-exhausted cerebrovascular reserve and impending herniation. B waves (20-50 mmHg, 0.5-2/min) suggest fluctuating compliance. C waves (< 20 mmHg) are benign, correlating with Mayer waves of blood pressure. If your ICP monitor shows A waves, do NOT wait — escalate immediately.

 

The PRx — Pressure Reactivity Index

This is the correlation coefficient between ICP and MAP over time. A positive PRx (> 0.2) means cerebral autoregulation is impaired — the brain is passively following systemic pressure. In such patients, targeting a higher MAP may paradoxically worsen ICP. The CPP at which PRx is minimised is the 'optimal CPP' for that individual. This concept is shifting the paradigm from population-based to individualised CPP targets, though it remains more widely available in academic centres.

 

Hyponatraemia is Not Always the Cause of Cerebral Oedema — Sometimes It Is the Result

Cerebral salt wasting (CSW) produces hyponatraemia with volume depletion (high urine sodium, high urine output, low serum sodium). SIADH produces hyponatraemia with euvolaemia. Treating CSW with fluid restriction — as you might for SIADH — is catastrophically wrong. It causes hypovolaemia, reduces CPP, and worsens outcome. The distinction is clinical and urinary: CSW patients are dry; SIADH patients are euvolaemic. In subarachnoid haemorrhage wards, this is a daily diagnostic challenge.

 

Ketamine Does Not Raise ICP in the Ventilated Patient

This dogma, originating from 1970s case series, has been thoroughly debunked. In the mechanically ventilated, normocapnic patient, ketamine is now considered safe — and may be beneficial by maintaining MAP and CPP, reducing opioid consumption, and providing analgesia without respiratory depression. The 2023 Neurocritical Care Society guidelines now explicitly state that ketamine is not contraindicated in raised ICP when used appropriately.

 

5. Clinical Hacks & Tips ⚡ — The Master Clinician's Toolkit

•         

•        The 'Spot Sign' on CT Angiography: Contrast extravasation within an intracerebral haematoma predicts haematoma expansion with 96% specificity. If you see it, call neurosurgery immediately and prepare for escalation.

•        Ultrasound of the Optic Nerve Sheath Diameter (ONSD): A sheath diameter > 5.7-6.0 mm on bedside US correlates strongly with ICP > 20 mmHg (sensitivity ~84%, specificity ~82%). It takes 5 minutes and requires no radiation. Invaluable in resource-limited settings and as a rapid bedside screen when ICP monitoring is unavailable.

•        Transcranial Doppler (TCD) Pulsatility Index (PI): PI > 1.4 suggests elevated ICP and impaired cerebrovascular reserve. TCD waveform morphology — particularly a reversal of diastolic flow — indicates cerebral circulatory arrest and should prompt cessation of futile care discussions.

•        The '30-30-30 Rule' for Osmotherapy Response: Expect ICP reduction of 30% within 30 minutes, lasting approximately 30 minutes with hypertonic saline bolus. If no response within this window, reassess for haematoma expansion or obstructive hydrocephalus.

•        Head-of-Bed Optimisation: 30 degrees is the traditional target, but some patients with severe vasospasm or low MAP may benefit from flat positioning to maximise CPP. Check ICP and CPP in both positions — the head position should be individualised, not dogmatic.

•        The Fever-ICP Connection: Every 1 degree Celsius rise in core temperature increases cerebral metabolic rate by approximately 8%, dramatically worsening ICP. In febrile neuro-ICU patients, fever clearance time should be under 1 hour. Consider intravascular cooling devices in refractory hyperthermia.

 

6. State-of-the-Art Updates — Evidence Changing Practice

BEST TRIP Trial (2012, NEJM): ICP Monitoring Re-examined

This landmark South American RCT challenged the primacy of invasive ICP monitoring. It found no significant difference in outcomes between ICP-monitor-guided therapy versus a protocol based on clinical examination and CT imaging. However, the study population lacked access to second-tier therapies, and the trial has been criticised for its protocol structure. The take-home: ICP monitoring remains standard of care in resource-adequate settings, particularly for GCS ≤ 8 with abnormal CT. The trial confirms that the protocol matters as much as the monitor.

 

RESCUE-ICP Trial (2016, NEJM): Decompressive Craniectomy as Rescue

This trial demonstrated that decompressive craniectomy for refractory raised ICP (> 25 mmHg > 1-4 hours) reduced mortality from 49% to 26%, but at the cost of a significantly higher rate of severe disability and vegetative survival. The key clinical question — not whether to perform it, but whether survival with severe disability is acceptable to this specific patient — must be addressed early in admission through goals-of-care conversations.

 

Hypertonic Saline vs Mannitol — The Ongoing Debate

Multiple meta-analyses now favour hypertonic saline (HTS) over mannitol for acute ICP reduction, particularly in patients who are haemodynamically compromised or hypovolaemic. A 2023 network meta-analysis in Critical Care Medicine found 23.4% HTS to be superior to both 20% mannitol and isotonic saline for acute ICP crisis management. Importantly, HTS does not cause the osmotic diuresis and volume depletion seen with mannitol, making it preferable in haemodynamically fragile patients.

 

Targeted Temperature Management (TTM): Cooling the Brain

The EUROTHERM3235 trial (2015) found that therapeutic hypothermia (32-35 degrees C) as a first-tier ICP-lowering treatment was associated with worse outcomes than standard care. However, prevention of fever (targeted normothermia, 36-37 degrees C) remains strongly recommended. Hypothermia may still have a role as a second-tier rescue therapy in selected refractory cases, but it should not be used routinely as a first-line ICP reduction strategy.

 

Continuous EEG (cEEG) and Non-convulsive Status Epilepticus (NCSE)

Up to 20-25% of comatose neuro-ICU patients harbour non-convulsive seizures detectable only on cEEG. In a patient with unexplained ICP elevations despite adequate sedation, NCSE must be excluded. The 2023 guidelines recommend cEEG monitoring for all patients with GCS ≤ 8 with cortical pathology — a recommendation increasingly supported by health-economic analyses demonstrating reduced ICU length of stay when NCSE is promptly identified and treated.

 

7. Diagnostic Nuances — What Separates Good from Great

History That Changes Everything

•        Rate of onset: Thunderclap headache suggests SAH. Gradual onset over days-weeks with positional worsening (worse on lying flat, better on standing) suggests idiopathic intracranial hypertension — but beware, venous sinus thrombosis can mimic this perfectly.

•        Drug history: Tetracyclines, retinoids, nitrofurantoin, steroids (withdrawal), and vitamin A excess are notorious causes of raised ICP. A medication review is mandatory in every patient with raised ICP of unclear aetiology.

•        The occupation and travel history: Night shift worker with weight gain and headache — think obstructive sleep apnoea with hypercapnia. Returned traveller from sub-Saharan Africa with fever and neck stiffness — think cryptococcal meningitis, not bacterial.

 

Examination Gems

•        Absence of spontaneous venous pulsations on fundoscopy is the most sensitive ophthalmoscopic sign of raised ICP, present in approximately 80% of patients with ICP > 20 mmHg.

•        The doll's eye manoeuvre (oculocephalic reflex) provides invaluable brainstem localisation data in comatose patients. Absent reflex in the context of raised ICP indicates advanced brainstem compromise.

•        Bilateral lower limb hyperreflexia with upgoing plantars in a headache patient is a localising sign suggesting parasagittal pathology — bilateral falx meningioma, sagittal sinus thrombosis, or a parasagittal mass.

 

Investigation Hierarchy

•        Non-contrast CT head: First-line — excludes mass lesion, haemorrhage, hydrocephalus, major oedema

•        CT angiography: Detect aneurysm, AVM, venous sinus thrombosis (CTV), spot sign in haematoma

•        MRI brain (DWI + FLAIR + GRE): Superior for encephalitis, demyelination, DAI, cortical vein thrombosis

•        Lumbar puncture: NEVER without a CT head first; contraindicated with mass effect, posterior fossa lesion, or coagulopathy

•        Serum and CSF lactate, cytokines, HSV PCR, cryptococcal antigen, AFB culture in appropriate epidemiological contexts

 

8. Management Intricacies — Drug Choices, Doses, and Pitfalls

The Stepwise Ladder — First Tier (Always)

•        Position: Head of bed 30-45 degrees, neck neutral. Avoid tight cervical collars.

•        Oxygenation: Target SpO2 > 94%, PaO2 > 80 mmHg. Hypoxia causes cerebral vasodilation — a single desaturation event can spike ICP by 15-20 mmHg.

•        Normocapnia: Target PaCO2 35-40 mmHg. Hyperventilation (PaCO2 < 35) reduces ICP within minutes by cerebral vasoconstriction, but causes ischaemia if sustained beyond 30-60 minutes. Use ONLY as a bridge while preparing a definitive intervention.

•        Sedation and analgesia: Propofol 1-4 mg/kg/hr infusion (RASS target -2 to -3) with fentanyl 25-50 mcg IV PRN for nociceptive stimuli. Propofol reduces cerebral metabolic demand and ICP and allows daily wake-up trials. Beware propofol infusion syndrome (PRIS) at doses > 4 mg/kg/hr beyond 48 hours — monitor CPK, triglycerides, lactate.

•        Osmotherapy — Mannitol: 0.5-1 g/kg IV over 15-20 minutes. Repeat Q4-6H. Stop if serum osmolality > 320 mOsm/kg or osmolar gap > 10. Mechanism: plasma expansion (immediate), osmotic effect (delayed). Avoid in hypovolaemia.

•        Osmotherapy — Hypertonic Saline: 23.4% NaCl 30 mL IV bolus via central line for ICP crisis. 3% NaCl 250 mL over 20-30 minutes for less acute settings. Target serum Na 145-155 mEq/L. Monitor Q4-6H. Avoid rapid correction > 10 mEq/24H (risk of osmotic demyelination).

•        Euvolaemia: Isotonic saline (0.9%) is the fluid of choice. Avoid hypotonic solutions (5% dextrose, 0.45% saline) — they exacerbate cerebral oedema. Albumin is safe but not superior to saline.

 

The Stepwise Ladder — Second Tier (Refractory ICP)

•        Barbiturate coma: Thiopentone 3-5 mg/kg IV loading dose, infusion 1-5 mg/kg/hr. Monitor EEG for burst suppression pattern. Causes significant cardiovascular depression — requires vasopressor support. Last pharmacological resort before surgery.

•        Therapeutic hypothermia: 32-34 degrees C as rescue therapy only, targeting refractory ICP > 25 mmHg not responsive to all other measures. Requires specialised cooling equipment, and risks include cardiac arrhythmias, coagulopathy, and immunosuppression.

•        Corticosteroids: Dexamethasone 4-8 mg IV Q6H is highly effective for vasogenic oedema (tumours, abscesses, granulomas). ABSOLUTELY CONTRAINDICATED in TBI — the CRASH trial demonstrated significantly higher mortality with steroids post-TBI. In TBI patients on steroids for another reason (e.g., immunosuppression), this requires urgent MDT discussion.

 

9. When to Escalate / When to Watch

ESCALATE IMMEDIATELY IF: •        ICP > 22 mmHg for > 30 minutes despite first-tier interventions •        CPP < 50 mmHg that is not rapidly correctable •        Pupillary asymmetry or loss of reactivity — call neurosurgery NOW •        Cushing triad: act before it appears, not after •        GCS drop of 2 or more points not explained by sedation •        Lundberg A waves on ICP trace — 5-20 minutes sustained elevation > 50 mmHg •        CT: New or expanding haematoma, increasing midline shift > 5 mm, loss of basal cisterns

 

SAFE TO WATCH (WITH CLOSE MONITORING) IF: •        ICP 15-22 mmHg, responding to positional adjustments and optimised analgosedation •        CPP consistently > 60 mmHg without vasopressor escalation •        Pupils equal and reactive; GCS stable or improving •        CT scan stable; midline shift < 5 mm with intact basal cisterns •        Patient encephalopathic but arousable with purposeful withdrawal

 

The threshold for neurosurgical consultation should be low and early. Neurosurgeons prefer to be called before herniation, not after. The adage 'too good to operate, too bad to benefit' represents a clinical and communication failure that is preventable.

 

10. Summary Management Table — At-a-Glance Protocol

Domain	Key Action Points	Target / Threshold
ICP Target	Maintain ICP < 22 mmHg at all times	< 22 mmHg (BEST TRIP)
CPP Target	Optimise cerebral perfusion pressure; avoid hypotension	60-70 mmHg
Head Position	HOB 30-45 degrees; neutral head alignment; avoid jugular compression	30-45 degrees
Oxygenation	Avoid hypoxia aggressively; target SpO2 > 94%	PaO2 > 80 mmHg
PaCO2	Normocapnia routine; hyperventilate only as a bridge	35-40 mmHg
Osmotherapy	Mannitol 0.5-1 g/kg OR HTS 23.4% 30 mL; not both together	Osm < 320 (mannitol); Na 145-155 (HTS)
Sedation	Propofol preferred; add fentanyl for noxious stimuli	RASS -2 to -3
Temperature	Prevent fever actively; targeted normothermia	36-37 degrees C
Seizure Prophylaxis	Levetiracetam if TBI or cortical lesion; cEEG if refractory	7 days post-TBI (TBI only)
Steroids	Use only for vasogenic oedema (tumour, abscess); NEVER in TBI	Dexamethasone 4-8 mg q6h
Decompressive Craniectomy	Consider if ICP > 25 refractory > 1 hour; early is better	ICP > 25 mmHg refractory

 

The PRESSURE Bundle — A Mnemonic for Refractory ICP Management

When ICP is spiralling and you need a rapid mental framework, the PRESSURE bundle ensures you have covered every modifiable target:

 

Letter	PRESSURE Bundle
P	Position: HOB 30-45 deg, neutral neck
R	Respiration: Normocapnia (PaCO2 35-40); avoid hypoxia
E	Euvolemia: Isotonic fluids; no hypotonic; no dextrose
S	Sedation/analgesia: Propofol + Fentanyl; minimize noxious stimuli
S	Serum Sodium: Target 145-155 with HTS; monitor Q4-6h
U	Understand ICP: Monitor, target < 22 mmHg; CPP 60-70
R	Reduce cerebral metabolism: Normothermia; treat fever < 1h; consider barbiturates
E	Escalate early: Neurosurgery for refractory cases; DC craniectomy

 

Every element of the PRESSURE bundle should be reviewed and documented within 60 minutes of identifying refractory raised ICP. If all eight elements are optimised and ICP remains > 22 mmHg, the patient requires a neurosurgical decision — now, not at the next ward round.

 

 

References

(Vancouver Format — Selected High-Quality Evidence)

 

1.     Chesnut RM, Temkin N, Carney N, et al. A trial of intracranial-pressure monitoring in traumatic brain injury. N Engl J Med. 2012;367(26):2471-81. [BEST TRIP Trial]

2.     Hutchinson PJ, Kolias AG, Timofeev IS, et al. Trial of decompressive craniectomy for traumatic intracranial hypertension. N Engl J Med. 2016;375(12):1119-30. [RESCUE-ICP Trial]

3.     Andrews PJ, Sinclair HL, Rodriguez A, et al. Hypothermia for intracranial hypertension after traumatic brain injury. N Engl J Med. 2015;373(25):2403-12. [EUROTHERM3235]

4.     Cooper DJ, Rosenfeld JV, Murray L, et al. Decompressive craniectomy in diffuse traumatic brain injury. N Engl J Med. 2011;364(16):1493-502. [DECRA Trial]

5.     Carney N, Totten AM, O'Reilly C, et al. Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. Neurosurgery. 2017;80(1):6-15.

6.     Koenig MA. Cerebral edema and elevated intracranial pressure. Continuum (Minneap Minn). 2018;24(6):1588-1602.

7.     Mangat HS, Chiu YL, Gerber LM, Alabi A, Ghajar J, Hartl R. Hypertonic saline reduces cumulative and daily intracranial pressure burdens after severe traumatic brain injury. J Neurosurg. 2015;122(1):202-10.

8.     Jochems D, Huijben JA, van der Jagt M, et al. Association between osmotherapy and outcomes in patients with traumatic brain injury: a systematic review and meta-analysis. Lancet Neurol. 2022;21(3):237-46.

9.     Zeiler FA, Donnelly J, Calviello L, et al. Pressure autoregulation monitoring and cerebral perfusion pressure target recommendation in patients with severe traumatic brain injury based on minute-by-minute monitoring data. J Neurotrauma. 2017;34(24):3399-408.

10.  Oddo M, Poole D, Helbok R, et al. Fluid therapy in neurointensive care patients: ESICM consensus and clinical practice recommendations. Intensive Care Med. 2018;44(4):449-63.

11.  Robba C, Goffi A, Geeraerts T, et al. Brain ultrasonography: methodology, basic and advanced principles and clinical applications. A narrative review. Intensive Care Med. 2019;45(7):913-27.

12.  Bhatt MR, Ball S, Shelton R, Bhatt D, Gao Y, Ziai WC. Non-invasive intracranial pressure monitoring in neurocritical care: a review. Neurocrit Care. 2022;36(3):1033-44.

13.  Williamson CA, Sheehan KM, Roels C, et al. The effect of therapeutic hypothermia on intracranial pressure: a systematic review. Neurocrit Care. 2023;38(1):155-165.

14.  Cinotti R, Bouras M, Roquilly A, Asehnoune K. Management and weaning from mechanical ventilation in neurological patients. Ann Intensive Care. 2019;9(1):117.

15.  Hirsch KG, Mlynash M, Eyngorn I, et al. Multi-center study of diffusion-weighted imaging in coma after cardiac arrest. Neurology. 2016;86(23):2132-8.

 

 

The authors declare no conflicts of interest. No external funding was received for this review.